

XTL Biopharmaceuticals to Present at IATI Biomed 2015 Conference

Raanana, ISRAEL May 11, 2015 — <u>XTL Biopharmaceuticals Ltd.</u> (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that the company will present at the IATI Biomed 2015 Conference on May 12, 2015:

Date: May 12, 2015

Presenter: Josh Levine, Chief Executive Officer

Time: 6:00 pm Israel Time

Location: Hall C6, Tel Aviv Convention Center, Israel

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of unmet clinical needs. XTL is focused on late stage clinical development of drugs for the treatment of lupus and multiple myeloma.

XTL is a public company traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares are included in the following indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.

For more information, the content of which is not part of this press release, please visit www.xtlbio.com

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Please see the risk factors associated with an investment in our ADSs or ordinary shares which are included in our Annual Report on Form 20-F as filed with the U.S. Securities and Exchange Commission on April 28, 2015.

Investor Contacts:

Investor Relations, XTL Biopharmaceuticals Ltd.

Tel: +972 9 955 7080 Email: <u>ir@xtlbio.com</u> <u>www.xtlbio.com</u>